Ramipril 2.5–10mg
Brand names: Tritace, Altace
Ramipril is an oral ACE inhibitor used in chronic kidney disease for blood pressure control and to slow progression, particularly where there is proteinuria, as well as in hypertension, heart failure and after myocardial infarction.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits angiotensin-converting enzyme, reducing angiotensin II and aldosterone; the resulting fall in efferent arteriolar tone lowers intraglomerular pressure and proteinuria in addition to lowering systemic blood pressure.
Prescribing in practice
- It is contraindicated in pregnancy and can cause acute kidney injury and hyperkalaemia, especially with volume depletion, NSAIDs, or in renovascular disease, so check renal function and potassium before and after starting or up-titrating.
- A modest initial rise in creatinine may be acceptable, but a large rise warrants review and exclusion of renal artery stenosis.
- Counsel on dry cough and the small risk of angioedema, and hold the drug during acute intercurrent illness with dehydration (sick-day guidance).
Monitoring
Check renal function and serum potassium before starting, after each dose increase, and periodically thereafter, along with blood pressure.
Counselling the patient
- Stop temporarily and seek advice if you have vomiting, diarrhoea or become dehydrated.
- Report a persistent dry cough or any swelling of the face, lips or tongue.
- Avoid over-the-counter anti-inflammatory painkillers unless advised.
Evidence & guidelines
Major trials demonstrate renoprotection and cardiovascular benefit, and NICE and current prescribing references support ACE inhibitors as first-line in proteinuric CKD.
Reference: REIN Trial (Lancet 1997); KDIGO CKD Guidelines 2024; NICE NG203; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019